相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Characterization of a clinical Clostridioides difficile isolate with markedly reduced fidaxomicin susceptibility and a V1143D mutation in rpoB
Julian Schwanbeck et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
The ClosER study: results from a three-year pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes, 2011-2014
J. Freeman et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
Diversity of Clostridium difficile PCR ribotypes in Europe: results from the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID), 2012 and 2013
K. A. Davies et al.
EUROSURVEILLANCE (2016)
Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571
Jennifer A. Leeds
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)
Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection
Patrizia Spigaglia
THERAPEUTIC ADVANCES IN INFECTIOUS DISEASE (2016)
Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes
J. Freeman et al.
CLINICAL MICROBIOLOGY AND INFECTION (2015)
Clostridium difficile Isolates with High Linezolid MICs Harbor the Multiresistance Gene cfr
Mercedes Marin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections
Christina M. Surawicz et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI
Thomas J. Louie et al.
CLINICAL INFECTIOUS DISEASES (2012)
Fidaxomicin Attains High Fecal Concentrations With Minimal Plasma Concentrations Following Oral Administration in Patients With Clostridium difficile Infection
Pamela Sears et al.
CLINICAL INFECTIOUS DISEASES (2012)
Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial
Oliver A. Cornely et al.
LANCET INFECTIOUS DISEASES (2012)
Comparative Susceptibilities to Fidaxomicin (OPT-80) of Isolates Collected at Baseline, Recurrence, and Failure from Patients in Two Phase III Trials of Fidaxomicin against Clostridium difficile Infection
Ellie J. C. Goldstein et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Use of different molecular typing methods for the study of heterogeneity within Clostridium difficile toxinotypes V and III
S. Janezic et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2011)
Clostridium difficile infection in Europe: a hospital-based survey
Martijn P. Bauer et al.
LANCET (2011)
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Thomas J. Louie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Health Care-Associated Clostridium difficile Infection in Canada: Patient Age and Infecting Strain Type Are Highly Predictive of Severe Outcome and Mortality
Mark Miller et al.
CLINICAL INFECTIOUS DISEASES (2010)
The Changing Epidemiology of Clostridium difficile Infections
J. Freeman et al.
CLINICAL MICROBIOLOGY REVIEWS (2010)
Clostridium difficile Isolates Resistant to Fluoroquinolones in Italy: Emergence of PCR Ribotype 018
Patrizia Spigaglia et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2010)
Emergence of reduced susceptibility to metronidazole in Clostridium difficile
Simon D. Baines et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates
F. Barbut et al.
CLINICAL MICROBIOLOGY AND INFECTION (2007)
分享论文
